ARMK surged 8.6% on May 12 after reporting earnings. Options traders piled into calls at a pace not seen in months. Simultaneously, short sellers cut positions at speed — and Baird lifted its price target to $58.
The put-call ratio hit 0.3357 on May 12. That sounds modest, but context matters. The 20-day mean PCR was just 0.104. The spike registered nearly 3.9 standard deviations above that average. Call volume swamped puts by a wide margin. Traders were not hedging — they were betting on further upside.
The PCR had been drifting lower through April, touching 0.052 on April 20. The reversal on earnings day was sharp and decisive.
Short interest fell 12% in one week to 3.74% of free float. That is the lowest level in over a month. With SI below 5% of float, this is not a heavily shorted stock. But the direction is clear. Positions have been trimmed steadily since mid-April, when SI stood closer to 4.6%.
The borrow market tells a slightly different story. Cost to borrow doubled week-on-week to 0.64%. That is the highest rate since late April. Availability remains very loose — short sellers face no structural squeeze. The CTB move likely reflects the burst of activity around earnings rather than a tightening lending pool.
The morning after earnings, Baird's Andrew Wittmann raised his price target from $50 to $58, maintaining an Outperform rating. At current prices near $48.41, that implies roughly 20% upside to Baird's target. The consensus mean sits at $51.44.
The analyst upgrade cycle has been consistent. UBS raised its target in April. Oppenheimer and Truist both raised targets earlier this year. The bull case centres on high single-digit organic growth, strong contract retention, and recent wins with RWJ Barnabas and Alabama Corrections.
The bear case points to inflation in food and labour costs, leverage, and weaker consumer spending. EV/EBITDA stands at 11.1x — not cheap, but the forward EPS momentum score ranks in the 94th percentile year-on-year.
The earnings event cluster — with three event timestamps on May 12 — appears to have passed cleanly. Whether the PCR spike and short covering sustain into next week, or fade as the post-earnings premium deflates, is the key question for the near term.
Data summary
See the live data behind this article on ORTEX.
Open ARMK on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
